Cue Biopharma reported a net loss of $153.1 million for the quarter ended June 30, 2026, driven by one-time non-cash losses and expenses related to its license agreement with Ascendant. Revenue increased to $7.9 million from collaboration milestones. The company completed a $50 million private placement financing subsequent to the quarter end to support clinical development. Key operational highlights include an IND submission for CUE-221 in food allergies, anticipated Phase 2 data readout by late Q3 2026, and leadership additions including new CMO Dr. Dominic Borie and CFO James M. Ahlers. Cue Biopharma is a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases.
